Physician profile
Stefan Somlo
NPI 1538144035
$110,602.86
in general payments reported to CMS, 2019-2025
6 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $6,030 · 2023: $20K · 2024: $35K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $83K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $82,585.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $75,375.00 | 2023-2025 | |
| Otsuka Pharmaceutical Co., LTD. | $21,987.86 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $6,030.00 | 2020 | |
| Janssen Research & Development, LLC | $3,600.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $3,185.00 | 2024 | |
| Pfizer INC. | $425.00 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Somlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.